OLOKIZUMAB
Rheumatoid Arthritis
R-Pharm International, LLCmonoclonal_antibodyPhase 3Dormant
BB
64/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 49/ 100
- Competitive Position
- 95/ 100
Competitive context
20 Active assets in the Rheumatoid Arthritis cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Naltrexone Truway Health, Inc. | Phase 4 | BBB |
METHOTREXATE National Institute of Allergy and Infectious Diseases (NIAID) | Phase 3 | BB |
IBUPROFEN Amgen | Phase 3 | BB |
Tocilizumab Hoffmann-La Roche | Phase 3 | BB |
Buprenorphine Mundipharma Pte Ltd. | Phase 4 | BB |
View all 38 →
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →